Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Gross Profit (2021 - 2025)

InMed Pharmaceuticals' Gross Profit history spans 5 years, with the latest figure at $184194.0 for Q4 2025.

  • For Q4 2025, Gross Profit fell 60.04% year-over-year to $184194.0; the TTM value through Dec 2025 reached $1.3 million, down 21.65%, while the annual FY2025 figure was $1.7 million, 55.02% up from the prior year.
  • Gross Profit reached $184194.0 in Q4 2025 per INM's latest filing, down from $403159.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $1.6 million in Q2 2023 to a low of -$491018.0 in Q3 2022.
  • Average Gross Profit over 5 years is $314202.0, with a median of $249714.0 recorded in 2022.
  • The largest YoY upside for Gross Profit was 2222.82% in 2024 against a maximum downside of 70.32% in 2024.
  • A 5-year view of Gross Profit shows it stood at $111555.0 in 2021, then rose by 17.58% to $131163.0 in 2022, then soared by 147.13% to $324142.0 in 2023, then skyrocketed by 42.19% to $460894.0 in 2024, then tumbled by 60.04% to $184194.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Gross Profit are $184194.0 (Q4 2025), $403159.0 (Q3 2025), and $576654.0 (Q2 2025).